Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany)
Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ilieva, Y. [verfasserIn] Kaloyanov, K. [verfasserIn] Yosifov, D. [verfasserIn] Robev, B. [verfasserIn] Zhelezova, I. [verfasserIn] Genova, M. [verfasserIn] Mihova, A. [verfasserIn] Balatzenko, G. [verfasserIn] Zaharieva, M. M. [verfasserIn] Berger, M. R. [verfasserIn] Konstantinov, S. M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phytochemistry reviews - Dordrecht : Springer Science + Business Media B.V., 2002, 13(2014), 2 vom: 23. Apr., Seite 459-469 |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2014 ; number:2 ; day:23 ; month:04 ; pages:459-469 |
| Links: |
|---|
| DOI / URN: |
10.1007/s11101-014-9351-7 |
|---|
| Katalog-ID: |
SPR01665742X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR01665742X | ||
| 003 | DE-627 | ||
| 005 | 20230519091453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201006s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11101-014-9351-7 |2 doi | |
| 035 | |a (DE-627)SPR01665742X | ||
| 035 | |a (SPR)s11101-014-9351-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 580 |a 540 |q ASE |
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Ilieva, Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. | ||
| 650 | 4 | |a Anticlastogenic effect |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antineoplastic activity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CTCL |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Curcumin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical treatment |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kaloyanov, K. |e verfasserin |4 aut | |
| 700 | 1 | |a Yosifov, D. |e verfasserin |4 aut | |
| 700 | 1 | |a Robev, B. |e verfasserin |4 aut | |
| 700 | 1 | |a Zhelezova, I. |e verfasserin |4 aut | |
| 700 | 1 | |a Genova, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Mihova, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Balatzenko, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Zaharieva, M. M. |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, M. R. |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinov, S. M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytochemistry reviews |d Dordrecht : Springer Science + Business Media B.V., 2002 |g 13(2014), 2 vom: 23. Apr., Seite 459-469 |w (DE-627)340872543 |w (DE-600)2065661-0 |x 1572-980X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g number:2 |g day:23 |g month:04 |g pages:459-469 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11101-014-9351-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | b | k | |a 42.00 |q ASE |
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |e 2 |b 23 |c 04 |h 459-469 | ||
| author_variant |
y i yi k k kk d y dy b r br i z iz m g mg a m am g b gb m m z mm mmz m r b mr mrb s m k sm smk |
|---|---|
| matchkey_str |
article:1572980X:2014----::niepatcoetaocruicoeaietdi |
| hierarchy_sort_str |
2014 |
| bklnumber |
42.00 |
| publishDate |
2014 |
| allfields |
10.1007/s11101-014-9351-7 doi (DE-627)SPR01665742X (SPR)s11101-014-9351-7-e DE-627 ger DE-627 rakwb eng 580 540 ASE 42.00 bkl Ilieva, Y. verfasserin aut Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 Kaloyanov, K. verfasserin aut Yosifov, D. verfasserin aut Robev, B. verfasserin aut Zhelezova, I. verfasserin aut Genova, M. verfasserin aut Mihova, A. verfasserin aut Balatzenko, G. verfasserin aut Zaharieva, M. M. verfasserin aut Berger, M. R. verfasserin aut Konstantinov, S. M. verfasserin aut Enthalten in Phytochemistry reviews Dordrecht : Springer Science + Business Media B.V., 2002 13(2014), 2 vom: 23. Apr., Seite 459-469 (DE-627)340872543 (DE-600)2065661-0 1572-980X nnns volume:13 year:2014 number:2 day:23 month:04 pages:459-469 https://dx.doi.org/10.1007/s11101-014-9351-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 42.00 ASE AR 13 2014 2 23 04 459-469 |
| spelling |
10.1007/s11101-014-9351-7 doi (DE-627)SPR01665742X (SPR)s11101-014-9351-7-e DE-627 ger DE-627 rakwb eng 580 540 ASE 42.00 bkl Ilieva, Y. verfasserin aut Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 Kaloyanov, K. verfasserin aut Yosifov, D. verfasserin aut Robev, B. verfasserin aut Zhelezova, I. verfasserin aut Genova, M. verfasserin aut Mihova, A. verfasserin aut Balatzenko, G. verfasserin aut Zaharieva, M. M. verfasserin aut Berger, M. R. verfasserin aut Konstantinov, S. M. verfasserin aut Enthalten in Phytochemistry reviews Dordrecht : Springer Science + Business Media B.V., 2002 13(2014), 2 vom: 23. Apr., Seite 459-469 (DE-627)340872543 (DE-600)2065661-0 1572-980X nnns volume:13 year:2014 number:2 day:23 month:04 pages:459-469 https://dx.doi.org/10.1007/s11101-014-9351-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 42.00 ASE AR 13 2014 2 23 04 459-469 |
| allfields_unstemmed |
10.1007/s11101-014-9351-7 doi (DE-627)SPR01665742X (SPR)s11101-014-9351-7-e DE-627 ger DE-627 rakwb eng 580 540 ASE 42.00 bkl Ilieva, Y. verfasserin aut Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 Kaloyanov, K. verfasserin aut Yosifov, D. verfasserin aut Robev, B. verfasserin aut Zhelezova, I. verfasserin aut Genova, M. verfasserin aut Mihova, A. verfasserin aut Balatzenko, G. verfasserin aut Zaharieva, M. M. verfasserin aut Berger, M. R. verfasserin aut Konstantinov, S. M. verfasserin aut Enthalten in Phytochemistry reviews Dordrecht : Springer Science + Business Media B.V., 2002 13(2014), 2 vom: 23. Apr., Seite 459-469 (DE-627)340872543 (DE-600)2065661-0 1572-980X nnns volume:13 year:2014 number:2 day:23 month:04 pages:459-469 https://dx.doi.org/10.1007/s11101-014-9351-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 42.00 ASE AR 13 2014 2 23 04 459-469 |
| allfieldsGer |
10.1007/s11101-014-9351-7 doi (DE-627)SPR01665742X (SPR)s11101-014-9351-7-e DE-627 ger DE-627 rakwb eng 580 540 ASE 42.00 bkl Ilieva, Y. verfasserin aut Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 Kaloyanov, K. verfasserin aut Yosifov, D. verfasserin aut Robev, B. verfasserin aut Zhelezova, I. verfasserin aut Genova, M. verfasserin aut Mihova, A. verfasserin aut Balatzenko, G. verfasserin aut Zaharieva, M. M. verfasserin aut Berger, M. R. verfasserin aut Konstantinov, S. M. verfasserin aut Enthalten in Phytochemistry reviews Dordrecht : Springer Science + Business Media B.V., 2002 13(2014), 2 vom: 23. Apr., Seite 459-469 (DE-627)340872543 (DE-600)2065661-0 1572-980X nnns volume:13 year:2014 number:2 day:23 month:04 pages:459-469 https://dx.doi.org/10.1007/s11101-014-9351-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 42.00 ASE AR 13 2014 2 23 04 459-469 |
| allfieldsSound |
10.1007/s11101-014-9351-7 doi (DE-627)SPR01665742X (SPR)s11101-014-9351-7-e DE-627 ger DE-627 rakwb eng 580 540 ASE 42.00 bkl Ilieva, Y. verfasserin aut Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 Kaloyanov, K. verfasserin aut Yosifov, D. verfasserin aut Robev, B. verfasserin aut Zhelezova, I. verfasserin aut Genova, M. verfasserin aut Mihova, A. verfasserin aut Balatzenko, G. verfasserin aut Zaharieva, M. M. verfasserin aut Berger, M. R. verfasserin aut Konstantinov, S. M. verfasserin aut Enthalten in Phytochemistry reviews Dordrecht : Springer Science + Business Media B.V., 2002 13(2014), 2 vom: 23. Apr., Seite 459-469 (DE-627)340872543 (DE-600)2065661-0 1572-980X nnns volume:13 year:2014 number:2 day:23 month:04 pages:459-469 https://dx.doi.org/10.1007/s11101-014-9351-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 42.00 ASE AR 13 2014 2 23 04 459-469 |
| language |
English |
| source |
Enthalten in Phytochemistry reviews 13(2014), 2 vom: 23. Apr., Seite 459-469 volume:13 year:2014 number:2 day:23 month:04 pages:459-469 |
| sourceStr |
Enthalten in Phytochemistry reviews 13(2014), 2 vom: 23. Apr., Seite 459-469 volume:13 year:2014 number:2 day:23 month:04 pages:459-469 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Anticlastogenic effect Antineoplastic activity CTCL Curcumin Topical treatment |
| dewey-raw |
580 |
| isfreeaccess_bool |
false |
| container_title |
Phytochemistry reviews |
| authorswithroles_txt_mv |
Ilieva, Y. @@aut@@ Kaloyanov, K. @@aut@@ Yosifov, D. @@aut@@ Robev, B. @@aut@@ Zhelezova, I. @@aut@@ Genova, M. @@aut@@ Mihova, A. @@aut@@ Balatzenko, G. @@aut@@ Zaharieva, M. M. @@aut@@ Berger, M. R. @@aut@@ Konstantinov, S. M. @@aut@@ |
| publishDateDaySort_date |
2014-04-23T00:00:00Z |
| hierarchy_top_id |
340872543 |
| dewey-sort |
3580 |
| id |
SPR01665742X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR01665742X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519091453.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11101-014-9351-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR01665742X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11101-014-9351-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">580</subfield><subfield code="a">540</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ilieva, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticlastogenic effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic activity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CTCL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Curcumin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaloyanov, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yosifov, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robev, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhelezova, I.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Genova, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mihova, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balatzenko, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaharieva, M. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, M. R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Konstantinov, S. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Phytochemistry reviews</subfield><subfield code="d">Dordrecht : Springer Science + Business Media B.V., 2002</subfield><subfield code="g">13(2014), 2 vom: 23. Apr., Seite 459-469</subfield><subfield code="w">(DE-627)340872543</subfield><subfield code="w">(DE-600)2065661-0</subfield><subfield code="x">1572-980X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:2</subfield><subfield code="g">day:23</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:459-469</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11101-014-9351-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">2</subfield><subfield code="b">23</subfield><subfield code="c">04</subfield><subfield code="h">459-469</subfield></datafield></record></collection>
|
| author |
Ilieva, Y. |
| spellingShingle |
Ilieva, Y. ddc 580 bkl 42.00 misc Anticlastogenic effect misc Antineoplastic activity misc CTCL misc Curcumin misc Topical treatment Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| authorStr |
Ilieva, Y. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)340872543 |
| format |
electronic Article |
| dewey-ones |
580 - Plants (Botany) 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1572-980X |
| topic_title |
580 540 ASE 42.00 bkl Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) Anticlastogenic effect (dpeaa)DE-He213 Antineoplastic activity (dpeaa)DE-He213 CTCL (dpeaa)DE-He213 Curcumin (dpeaa)DE-He213 Topical treatment (dpeaa)DE-He213 |
| topic |
ddc 580 bkl 42.00 misc Anticlastogenic effect misc Antineoplastic activity misc CTCL misc Curcumin misc Topical treatment |
| topic_unstemmed |
ddc 580 bkl 42.00 misc Anticlastogenic effect misc Antineoplastic activity misc CTCL misc Curcumin misc Topical treatment |
| topic_browse |
ddc 580 bkl 42.00 misc Anticlastogenic effect misc Antineoplastic activity misc CTCL misc Curcumin misc Topical treatment |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Phytochemistry reviews |
| hierarchy_parent_id |
340872543 |
| dewey-tens |
580 - Plants (Botany) 540 - Chemistry |
| hierarchy_top_title |
Phytochemistry reviews |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)340872543 (DE-600)2065661-0 |
| title |
Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| ctrlnum |
(DE-627)SPR01665742X (SPR)s11101-014-9351-7-e |
| title_full |
Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| author_sort |
Ilieva, Y. |
| journal |
Phytochemistry reviews |
| journalStr |
Phytochemistry reviews |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
txt |
| container_start_page |
459 |
| author_browse |
Ilieva, Y. Kaloyanov, K. Yosifov, D. Robev, B. Zhelezova, I. Genova, M. Mihova, A. Balatzenko, G. Zaharieva, M. M. Berger, M. R. Konstantinov, S. M. |
| container_volume |
13 |
| class |
580 540 ASE 42.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ilieva, Y. |
| doi_str_mv |
10.1007/s11101-014-9351-7 |
| dewey-full |
580 540 |
| author2-role |
verfasserin |
| title_sort |
antineoplastic potential of curcumin (cooperative study in bulgaria and germany) |
| title_auth |
Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| abstract |
Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. |
| abstractGer |
Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. |
| abstract_unstemmed |
Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
2 |
| title_short |
Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) |
| url |
https://dx.doi.org/10.1007/s11101-014-9351-7 |
| remote_bool |
true |
| author2 |
Kaloyanov, K. Yosifov, D. Robev, B. Zhelezova, I. Genova, M. Mihova, A. Balatzenko, G. Zaharieva, M. M. Berger, M. R. Konstantinov, S. M. |
| author2Str |
Kaloyanov, K. Yosifov, D. Robev, B. Zhelezova, I. Genova, M. Mihova, A. Balatzenko, G. Zaharieva, M. M. Berger, M. R. Konstantinov, S. M. |
| ppnlink |
340872543 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s11101-014-9351-7 |
| up_date |
2024-07-04T00:12:53.035Z |
| _version_ |
1803605217683439616 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR01665742X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519091453.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11101-014-9351-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR01665742X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11101-014-9351-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">580</subfield><subfield code="a">540</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ilieva, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The unfavorable safety of existing anticancer medications and the issue of multidrug resistance have fuelled the search for novel plant compounds as potential antineoplastic agents. One of the used approaches for identifying perspective candidates is based on ethnopharmacology. Curcumin is the yellow pigment of curry and has being employed in traditional Indian medicine. Within the EU it has the status of food ingredient (E100) and remains in many food additives. It is isolated from Curcuma longa L. and has been reported as NF-κB inhibitor and apoptosis inducer with antioxidant, cholesterol lowering, anti-inflammatory, anti-parasitic, antibacterial and antitumor potential. Curcumin has been shown to exert a wide spectrum of pleiotropic activities including antitumor effects and protection of the normal bone marrow. It possesses antineoplastic activity in various malignant cell lines in vitro, such as cutaneous T cell lymphoma, acute myeloid leukemia and urinary bladder cancer cells. In lymphoma and leukemia cell lines curcumin induces apoptosis as evidenced by caspase activation, PARP cleavage and oligonucleosomal DNA fragmentation. Expression of the myeloid marker CD13 (aminopeptidase N) is associated with faster apoptosis induction. In addition, curcumin causes concentration-dependent glutathione level increase. Application of curcumin in vivo resulted in protection against cisplatin-induced chromosomal aberrations (anticlastogenic effect). This finding reveals curcumin as preferable partner for combinations with antineoplastic agents in order to potentiate their activity and ameliorate the adverse effects. There is a clear need for new curcumin formulations because of its low bioavailability after oral intake. Cutaneous and intravesical curcumin applications remain a possibility for successful clinical use of curcumin.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticlastogenic effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic activity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CTCL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Curcumin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaloyanov, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yosifov, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robev, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhelezova, I.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Genova, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mihova, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balatzenko, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaharieva, M. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, M. R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Konstantinov, S. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Phytochemistry reviews</subfield><subfield code="d">Dordrecht : Springer Science + Business Media B.V., 2002</subfield><subfield code="g">13(2014), 2 vom: 23. Apr., Seite 459-469</subfield><subfield code="w">(DE-627)340872543</subfield><subfield code="w">(DE-600)2065661-0</subfield><subfield code="x">1572-980X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:2</subfield><subfield code="g">day:23</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:459-469</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11101-014-9351-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">2</subfield><subfield code="b">23</subfield><subfield code="c">04</subfield><subfield code="h">459-469</subfield></datafield></record></collection>
|
| score |
7.3998566 |